Feds Approve PED Vaccine for Import

Jan 30, 2014

After a meeting with provincial and territorial agricultural ministers, Federal Agriculture Minister Gerry Ritz announced Wednesday that the Canadian Food Inspection Agency (CFIA) will allow veterinarians to import a vaccine from the United States to deal with the pig-killing virus, porcine epidemic diarrhea or PED.

Thursday’s meeting was meant to address the growing concerns of PED. While the iPED + vaccine is new, preliminary studies have shown pigs that receive the vaccine develop antibodies against the virus. Harrisvaccines Inc. based in Ames, Iowa manufactures the vaccine.

PED is a highly contagious virus among swine, which has killed about 1 to 3 million pigs in the United States since last spring. The virus has since spread to Canada. The first confirmed case was found on a farm in Middlesex County, Ont.

“Today’s announcement is another step in the CFIA’s continuous efforts to work with the provinces to prevent PED from spreading in Canada,” Ritz said in a news release.

Government officials say that pig farmers should contact their attending veterinarian about accessing the vaccine. Veterinarians can apply for an import permit immediately.

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.